Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors  by Fung, Vincent W.H. et al.
Application of purging biotinylated liposomes from plasma to elucidate
influx and efflux processes associated with accumulation of
liposomes in solid tumors
Vincent W.H. Fung, Gigi N.C. Chiu, Lawrence D. Mayer*
Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Department of Advanced Therapeutics, British Columbia Cancer Research Center, 601 West 10th Ave., Vancouver, BC, Canada V5Z 1L3
Received 19 August 2002; received in revised form 3 December 2002; accepted 5 December 2002
Abstract
Although small, 100-nm liposomes are known to selectively accumulate in solid tumors, the individual contributions of liposome influx
and egress rates are not well understood. The aim of this work was to determine influx and efflux kinetics for 100-nm, 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC)/cholesterol (Chol) liposomes by inducing aggregate formation of biotinylated liposomes upon
administering avidin. Injecting 50 Ag of neutravidin intravenously to mice that had previously been administered 100 mg/kg DPSC/Chol
liposomes containing 0.5 mol% biotin-conjugated lipid resulted in >90% elimination of the liposomes from plasma within 1 h. This rapid
removal by the reticuloendothelial system (RES) permitted the determination of the tumor efflux kinetics due to negligible tumor influx after
neutravidin injection. The tumor efflux rate constant (k 1) was determined to be 0.041 h
 1 when neutravidin was injected 4 h after liposome
injection. This allowed the determination of the tumor influx rate constant (k1), which under these conditions was 0.022 h
 1. Therefore,
DSPC/Chol liposomal accumulation, in LS180 solid tumors, is dictated primarily by plasma liposome concentrations and liposome egress is
comparable or slightly faster than influx into the tumors. This method is applicable for a wide range of lipid doses, and can be used to
characterize influx and efflux parameters at different time points after accumulation. The application, therefore, has the potential to be used to
fully characterize the impact of different liposome parameters such as lipid composition, steric stabilization, size and dose on tumor
accumulation kinetics.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Liposomes have been widely employed as carrier sys-
tems for anticancer drugs and other agents. It is well
established that liposomes accumulate preferentially in dis-
ease sites, including tumors due to increases in tumor blood
vessel permeability [1–3]. However, little is known about
the detailed kinetic properties underlying liposome accumu-
lation in tumors. In particular, the relative contribution of
tumor influx and efflux of liposomes to the overall tumor
accumulation phenomenon has not been elucidated. More-
over, due to conflicting results arising from recent studies
that question the beneficial effects of liposome formulations
with extended half-lives [4–6], it has become increasingly
important to characterize the detailed mechanisms under-
lying tumor accumulation of liposomes.
Previous studies have described methods to clear lip-
osomes from the blood compartment to increase target-to-
blood ratios for rapid diagnostic imaging [7–9]. In this
approach, liposomes containing biotin-derivatized lipids
were administered intravenously followed by injection of
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avidin at times sufficient to allow liposome accumulation in
the disease site. Aggregates of liposomes formed in the
blood due to the high affinity between biotin and avidin
(Kdi10
 15 M) are rapidly recognized and cleared by the
reticuloendothelial system (RES), primarily in organs such
as the liver, spleen and lungs. However, these prior studies
utilized liposome doses for imaging that were approximately
10-fold lower than doses typically used for therapeutic
applications. In the present study, we have investigated the
use of biotin-labeled liposomes to elucidate the individual
contribution of influx and efflux rates to the net accumu-
lation of liposomes in solid tumors. The rapid removal of
liposomes provides the possibility of studying tumor efflux
in isolation because it eliminates the otherwise interfering
influx of liposomes from the circulation (Fig. 1). Liposomes
injected into tumor-bearing mice can be allowed to accu-
mulate in the tumor over a chosen time period. The
subsequent injection of neutravidin should rapidly clear
circulating liposomes, thereby allowing efflux of liposomes
from the tumor to be monitored over time. Determination of
the efflux rate constants from these data can then allow
tumor influx rate constants to be calculated based on known
plasma liposome concentrations. We adapted this approach
to studying tumor accumulation kinetics by optimizing
biotin–lipid content and neutravidin dose for rapid plasma
elimination. Tumor efflux and influx kinetics were deter-
mined for 100-nm, 1,2-distearoyl-sn-glycero-3-phosphocho-
line (DSPC)/cholesterol (Chol) using the LS180 human
colon carcinoma solid tumor xenograft model. Our results
have demonstrated the utility of this method in understand-
ing the mechanisms underlying accumulation of liposomes
in solid tumors. This information may greatly assist the
development of liposomal anticancer drug formulations with
improved therapeutic activity.
2. Materials and methods
2.1. Materials
DSPC and Chol were purchased from Avanti Polar
Lipids (Alabaster, AL). N-((6(biotinoyl)amino)hexanoyl)-
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (Biotin-
X-DSPE) was obtained from Northern Lipids (Vancouver,
BC). [3H]cholesteryl hexadecyl ether (CHE) was from
Amersham (Oakville, ON). HEPES and hydrogen peroxide
were purchased from Sigma Chemical (St. Louis, MO).
Neutravidin was obtained from Pierce Chemical (Rockford,
IL). Solvablek was from NEN Research Products (Dupont
Canada, Mississauga, ON, Canada). LS180 cells (a human
colon carcinoma cell line) were purchased from the ATCC
(Manassas, VA) and maintained in culture. CD-1 mice (20–
Fig. 1. Influx and efflux contribution of liposomal accumulation. During tumor accumulation of liposomes (gray circles), both influx and efflux take place (A),
with rate constants k1 and k 1, respectively. Rapid clearance of circulating liposomes (B) allows the isolation of a single kinetic variable, tumor efflux, as
shown in the accompanying equations, where Ltumor represents tumor liposome concentrations and Lblood represents blood liposome concentrations.
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23 g) and female SCID/RAG2 (25–26 g) were bred from
British Columbia Cancer Agency Animal Breeding Facility
(Vancouver, Canada).
2.2. Preparation of liposomes
DSPC/Chol/Biotin-X-DSPE (54.5:45:0.5 mole ratio) lip-
osomes were prepared using extrusion technology [10–12].
Lipids were dissolved in chloroform, and trace amount of
[3H]CHE was added as a non-exchangeable and non-
metabolizable lipid marker before drying down the mixture
to a homogenous lipid film under a stream of nitrogen gas
[13,14]. This resulting lipid film was placed under high
vacuum overnight to remove any residual chloroform.
Subsequently, the lipid film was hydrated in 20 mM/150
mM NaCl HEPES buffer (pH 7.5) (HBS) at 65 jC to a
final lipid concentration of 100 mg/ml to form multilamel-
lar vesicles. The resulting mixture was frozen in liquid
nitrogen and thawed five times followed by extrusion
through two stacked 0.08 Am pore size polycarbonate filters
(Nuclepore, Pleasanton, CA) using an extrusion device
(Northern Lipids, Vancouver, BC, Canada). The size of
the liposomes was determined by quasielastic light scatter-
ing (QELS) using a Nicomp submicron particle sizer model
370/270 (Pacific Scientific, Santa Barbara, CA) operating
at 632.8 nm. The mean diameter of these liposomes was
100F 10 nm.
2.3. In vitro aggregation
Liposomes (1 mg) of 100 nm diameter and neutravidin
(25 Ag) were incubated in a total volume of 750 Al HBS in
1.5 ml eppendorf tubes for 45 min at 37 jC with constant
shaking. Aliquots were removed and the size of liposomes
was determined by QELS at 5, 15, 30 and 45 min.
2.4. Plasma pharmacokinetics and tissue distribution of
liposomes
All in vivo studies were completed using protocols
approved by the University of British Columbia’s Animal
Care Committee, where these studies met the current guide-
lines of the Canadian Council of Animal Care. Liposomes,
labeled with [3H]CHE, were injected intravenously with
various lipid doses in 200 Al via the lateral tail vein. At
designated times, three mice were anesthetized with CO2
and whole blood was collected via cardiac puncture and
placed into EDTA-coated Microtainers (Becton Dickinson,
Lincoln Park, NJ). Plasma was isolated following centrifu-
gation at 4 jC for 15 min at 1000 g. Aliquoted plasma
samples (100 Al) were mixed with 5 ml Pico-Fluor 15
(Packard Biosciences, The Netherlands) scintillation fluid
for radioactivity counting.
Tissues including liver, spleen, lungs and tumors were
harvested and washed in saline and placed into preweighed
glass tubes. Tissue weights were determined before freezing
the samples at  70 jC. Appropriate volumes of distilled
water were added to tissues to achieve a 30% homogenate
(w/v) by homogenizing the mixture with a Polytron tissue
homogenizer (Kinematica, Lucerne, Switzerland). Aliquots
of the homogenate (200 Al) were added to 500 Al Solvable,
and the mixture was incubated at 50 jC for 3 h. After
cooling to room temperature, 50 Al of 200 mM EDTA, 200
Al of 30% hydrogen peroxide and 25 Al of 10 N HCl were
added. The mixture was then incubated for 1 h at room
temperature before adding 5 ml scintillation fluid for radio-
active counting. All tissue lipid levels were corrected for
lipid in the plasma compartment by using predetermined
plasma volume correction factors.
2.5. Liposome elimination from plasma via neutravidin
administration
To achieve rapid removal of biotinylated liposomes, the
effects of different doses of neutravidin on their pharmaco-
kinetics were studied. In the absence of neutravidin, the
elimination profile of DSPC/Chol/Biotin-X-DSPE (molar
ratio; 54.5:45:0.5) liposomes at a dose of 100 mg/kg was
initially studied in CD-1 mice over a 24-h period. Lip-
osomes were quantitated in plasma and various organs at 1,
4 and 24 h as described in Section 2.4.
To examine the effects of neutravidin on the biodistribu-
tion changes of biotinylated liposomes, various neutravidin
doses were injected into the tail vein at different times after
liposome injection. Plasma and various organs were then
sampled at the indicated times and liposomal levels were
measured as described in Section 2.4.
2.6. Tumor accumulation and plasma elimination studies of
biotinylated liposomes with and without neutravidin
Female SCID/RAG-2 mice were inoculated bilaterally
with 1106 LS180 cells subcutaneously on the hind
regions of the back. Once the tumors reached an estimated
mass of 0.5 g, mice were injected intravenously with 100
mg/kg dose of biotinylated liposomes. Tumor and plasma
liposomal levels were determined at 1, 2, 4, 8 and 24 h after
injection of liposomes. To characterize the effects of neu-
travidin on tumor and plasma levels of liposomes, neutra-
vidin was administered to mice 4 h post-injection of
liposomes. Liposome levels in both tumor and plasma were
then quantified at 1, 2, 4, 8 and 24 h after administration of
neutravidin. Tumor efflux behavior was then monitored;
efflux and influx rate constants were calculated using
pharmacokinetic equations and integral calculus.
2.7. Statistical analysis
Analysis of variance (ANOVA) was performed with the
statistical software package (Jmp-In. 4.0, Cary, NC) on the
results obtained after administration of the three neutravidin
doses. Differences were considered significant at P < 0.05.
V.W.H. Fung et al. / Biochimica et Biophysica Acta 1611 (2003) 63–69 65
3. Results
3.1. Aggregation by avidin in vitro
Liposome aggregation was initially evaluated in vitro to
ensure the incorporation of the biotinylated lipids in the
liposome formulation, the accessibility of the biotin moieties
on the liposome surface to neutravidin, and the formation of
liposome aggregates with neutravidin. The Biotin-X-DSPE
lipid used in this study contains an amino-hexanoyl spacer
that allows biotin to be extended away from the liposome,
thus increasing the exposure of the biotin moiety, compared
to biotin–DSPE [15]. Neutravidin was chosen because it
has less non-specific binding than that of avidin [16]. These
were two modifications made to previous protocols in the
hope of achieving more rapid liposome clearance from the
bloodstream.
Increases in liposome diameter were observed within 5
min of incubation with neutravidin, changing from a diam-
eter of 100F 10 to 380F 170 nm. It is important to note
that the mean diameter measured by QELS merely serves as
an indicator of aggregate formation, and should not be used
as an accurate measurement of the aggregate size. Because
aggregation is a random process, homogenous formation of
aggregates is not expected, which leads to broad size
distribution. After 45 min of incubation with neutravidin,
the mean diameter of liposomes was 720 nm with S.D. of
500 nm, indicating the heterogeneity and vast number of
aggregates present.
3.2. Effects of various doses of neutravidin on plasma
elimination and tissue distribution of biotinylated liposomes
The elimination profile of the biotinylated liposomes in
CD-1 mice injected with a lipid dose of 100 mg/kg but
without neutravidin was examined over a 24-h period. The
percentage injected dose remaining in plasma for biotiny-
lated liposomes were 50%, 31% and 5.5% at 1, 4 and 24 h,
respectively, whereas the percentage injected dose remain-
ing in plasma for non-biotinylated liposomes were 57%,
28% and 7.3% at 1, 4 and 24 h, respectively. This indicates
that the incorporation of biotin-derivatized lipids did not
alter the inherent plasma pharmacokinetics of the non-
biotinylated liposomal formulation.
One hour after liposome injection, neutravidin was
administered to induce rapid clearance of biotinylated lip-
osomes. All three neutravidin doses resulted in at least 95%
clearance of liposomes from the plasma within 1 h after
injection of the protein (Fig. 2). The lipid levels decreased
from a mean of about 1350 Ag lipid/g plasma at t = 1 h to a
mean of less than 50 Ag lipid/g plasma at t = 2 h. The cleared
liposomes were observed to accumulate in the RES organs.
The neturavidin-induced clearance properties exhibited
modest dose dependency, with 200 Ag neutravidin giving
rise to a mean plasma elimination in 1 h of approximately
99%, 98% with 100 Ag and 95% with 50 Ag neutravidin.
The differences, however, were not statistically significant
(ANOVA, P>0.05). Compared to the mice injected with 50
Ag neutravidin, the mice with 100 and 200 Ag neutravidin
were sluggish, tired, and were not as active throughout the
1-h period. This could be attributed to the elevated accu-
mulation of liposomes in the lungs observed for these
groups as shown in Fig. 2. In the groups administered with
100 and 200 Ag dose of neutravidin, the mean lipid levels in
the lungs were approximately 2000 and 2700 Ag lipid/g
tissue, respectively, compared to a mean lipid level of about
150 Ag/g tissue in the group treated with 50 Ag neutravidin.
Therefore, 50 Ag dose of neutravidin was chosen for
subsequent experiments to avoid untoward pulmonary reac-
tions.
Mice were sacrificed at 15, 30, 45 and 60 min post-
neutravidin administration (50 Ag dose) to evaluate the
kinetics of neutravidin-induced removal of the liposomes.
The removal of liposomes after neutravidin was a rapid
process as shown in Fig. 3. More than 70% of lipids were
cleared within 15 min, and over 90% were cleared within
1 h.
3.3. Effects of liposomal dose and administration times on
neutravidin-induced liposome clearance
In addition to examining the effects of neutravidin on
liposomes dosed at 100 mg/kg, a 10 mg/kg lipid dose was
also studied to evaluate the versatility and applicability of
the rapid neutravidin-based liposome clearance. As shown
in Table 1, administration of 50 Ag neutravidin resulted in
greater than 95% of 10 mg/kg lipid dose eliminated from
plasma in 1 h. The effects of administering neutravidin at 4
and 8 h after the initial liposome injection were also
Fig. 2. Biodistribution of DSPC/Chol/Biotin-X-DSPE liposomes with
various doses of neutravidin. Biotinylated liposomes (100 mg/kg and 100
nm in diameter) were injected into female CD-1 mice, and various doses of
neutravidin were administered (50, 100, 200 Ag) 1 h after liposome
injection. Liver (black bars), spleen (hatched bars), lungs (gray bars) and
plasma (white bars) were quantified for liposomal lipid levels 1 h after
neutravidin injection. Each bar represents the meanF S.D. for three
animals.
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assessed for the lipid dose of 100 mg/kg. Rapid removal of
liposomes was also seen at these time points, with greater
than 95% lipid being cleared within 30 min (Table 1). The
30-min time point was chosen to reduce potential false-
positive results with neutravidin’s effects. This relates to the
possibility that a low lipid level at 1 h after neutravidin
administration may be related to the lower liposomal lipid
concentrations present at t = 4 and 8 h.
3.4. Liposomal pharmacokinetics in tumor-bearing mice
and characterization of tumor efflux and influx
Lipid levels were measured in established LS180 solid
tumors and plasma over a 24-h period after a single intra-
venous injection of biotinylated liposomes (100 mg/kg). In
Fig. 4, plasma liposome levels are shown in panel A, and
tumor liposome levels are shown in panel B. The plasma
levels declined from about 1800 Ag lipid/g plasma at t = 1 h
to 1300 Ag lipid/g plasma at t = 4 h, and then slowly dropped
to about 500 Ag lipid/g plasma at t= 24 h. Liposomal levels
in tumor tissue increased to about 100 Ag lipid/g tumor at
t = 4 h, and then peaked at about 120 Ag lipid/g tumor at t = 8
h. The tumor levels appeared to plateau after this time as the
levels fell to about 110 Ag lipid/g tumor at t= 24 h. In a
matched group of tumor-bearing mice, neutravidin was
administered 4 h post injection of liposomes. A rapid
decrease in plasma lipid levels was induced, and lipid levels
decreased from a mean of about 1300 Ag lipid/g plasma at
t = 4 h to < 150 Ag lipid/g plasma within 1 h. The lipid levels
remained below the limit of quantitation (about 10 Ag of
lipid/g plasma) over the subsequent 23-h period as indicated
from the absence of data between t= 6 h and t = 28 h in Fig. 4
(panel A). Tumor lipid levels were also observed to gradually
Table 1
Percentage removal of plasma liposomal lipid (DSPC/Chol/Biotin-X-DSPE
liposomes) in female CD-1 mice after administration of 50 Ag neutravidin
Neutravidin-induced liposomal plasma removal (percentage of control)
Lipid dose (mg/kg) Time (h) Percentage removal (S.D.)
100 1a 95 (1)
4b 98 (2)
8b 96 (1)
10 1a 97 (1)
a Plasma levels were taken 1 h after neutravidin injection.
b Plasma levels were taken 30 min after neutravidin injection.
Fig. 3. Plasma elimination of DSPC/Chol/Biotin-X-DSPE liposomes with
neutravidin over 1 h. Biotinylated liposomes (100 mg/kg and 100 nm in
diameter) were injected into female CD-1 mice. Fifty micrograms of
neutravidin was administered 1 h after liposomal injection. Plasma
liposomal lipid levels were quantified 15, 30, 45 and 60 min post-injection
of neutravidin, as described in Section 2. Each data point represents the
meanF S.D. for three animals.
Fig. 4. Plasma elimination and tumor accumulation of DSPC/Chol/Biotin-
X-DSPE liposomes with (triangles) and without (squares) administration of
neutravidin. Biotinylated liposomes (100 mg/kg and 100 nm in diameter)
were injected into SCID/RAG2 mice bearing LS180 solid tumor. Panels A
and B represent plasma and tumor liposomal lipid levels, respectively.
Tumor and plasma liposomal lipid levels were determined at 1, 2, 4, 8 and
24 h. Fifty micrograms of neutravidin was administered at 4 h after
liposome injection, and tumor and plasma liposomal lipid levels were
determined at 1, 2, 4, 8 and 24 h after neutravidin administration. Data
points represent mean and S.D. from six tumors. Plasma lipid levels were
below the limit of quantitation at 6, 8, 12 and 28 h after neutravidin
injection.
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decrease over 24 h after neutravidin addition (Fig. 4, panel
B). The levels decreased from 100 Ag lipid/g tumor at t = 4 h
to about 30 Ag lipid/g tumor at t= 28 h. The efflux curve was
fitted, using the Microcal Origin software package (version
5.0), utilizing the least squares principles which indicates
that the efflux curve followed first-order kinetics (Fig. 5).
The efflux rate constant (k 1) was then estimated by fitting
the curve by a first-order kinetic equation and calculating it
from the slope using Eq. (1):
log y ¼ log y0  k1t=2:303 ð1Þ
where y represents tumor liposome concentration at time t, y0
represents tumor liposome concentration at t= 0, and k 1
represents tumor efflux rate constant for liposomes. From the
slope of the fitted curve (see Fig. 5), the tumor efflux rate
constant for liposomes (k 1) at t = 4 h was determined to be
0.041 h 1. Based on the assumption that at any given point
in time, the rate of change of tumor lipid levels is equal to the
difference between the products of the concentrations in the
individual pharmacokinetic compartments and their respec-
tive rate constants (see Fig. 1), the influx rate constant (k1)
can be calculated using Eqs. (2) and (3):
dy=dt ¼ k1½C  k1½y ð2Þ
where C represents plasma liposome concentration at 4 h.
Integrating both sides of Eq. (2) yields Eq. (3):
y ¼ ðk1=k1Þ½Cð1 ek1tÞ ð3Þ
Applying the tumor efflux rate constant (k 1) of 0.041 h
 1,
plasma liposome concentration (C) of 1307 Ag/g at 4 h, and
tumor liposome concentration ( y) of 106 Ag/g at 4 h to Eq.
(3) yielded a value of 0.022 h 1 for k1.
4. Discussion
Liposomes have been utilized extensively as drug deliv-
ery vehicles for anticancer agents, with several such prod-
ucts approved for therapeutic use in cancer patients. An
increasing focus has been placed on designing liposomes
with extended circulation longevity, which is believed to
improve tumor site delivery through increased plasma lip-
osome concentrations where small, 100-nm liposomes
would preferentially extravasate across the leaky vasculature
of solid tumors and accumulate to high levels [1–3].
However, modifications to liposome physical properties
such as surface-grafted hydrophilic polymers [e.g. poly(-
ethylene glycol) (PEG)] may possibly alter both influx and
efflux rates that contribute to the net flux, or accumulation,
of liposomes in solid tumors. Furthermore, liposome influx
and efflux rates may be differentially affected by such
formulation changes. In this study, we utilized avidin
cross-linking of liposomes to rapidly deplete liposomes
from the blood compartment, thereby allowing the determi-
nation of liposome tumor efflux and influx rates. We have
evaluated this methodology to establish its utility in char-
acterizing the detailed tumor accumulation properties of
liposomal drug delivery systems.
Other laboratories have employed avidin-induced re-
moval of circulating liposomes to improve target-to-back-
ground ratio for imaging and diagnostic purposes [7–9]. Our
aim was to optimize the clearance properties to study the
kinetics of liposome efflux and influx in solid tumors. It is
important to elucidate these variables because accumulation
levels in the tumor (in both absolute and dynamic terms) are
dependent on the combination of these processes. A low
maximum tumor accumulation value may indicate a high
efflux and/or slow influx, and vice versa. Consequently, we
believe that plasma levels are neither the most accurate
predictor nor the ultimate governing factor for tumor levels,
and that a detailed pharmacokinetic characterization such as
that presented here will help to elucidate the effect of specific
liposome properties on tumor uptake properties.
At any point in time during tumor accumulation, both
processes of influx and efflux occur simultaneously, making
it difficult to determine the individual variables. Rapid
removal of liposomes from the circulation, however, permits
the isolation and thus the characterization of a single kinetic
variable—tumor efflux, by eliminating the otherwise inter-
fering influx factor that is due to accumulating liposomes
from plasma (Fig. 1). Unlike other studies that simply aim to
obtain a relative improvement in clearance [7–9], rapid
clearance is crucial in the present study as we do not want
tumor influx to obscure efflux monitoring. It is shown from
our results that after neutravidin injection, plasma levels
remain minimal throughout the efflux process, and thus
Fig. 5. A plot of the logarithm values of tumor liposome concentrations as a
function of the time following neutravidin administration to determine the
tumor efflux rate constant, k 1, for biotinylated DSPC/Chol liposomes.
Data for tumor liposome concentrations were derived from Fig. 4B. The
line was fitted to the data points using Microcal Origin software (version
5.0), and the slope was used to calculate k 1.
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there is minimal interference from the influx process. The
present study has successfully achieved rapid elimination of
DSPC/Chol liposomes of 100 nm in size and lipid doses of
10 and 100 mg/kg by incorporating 0.5% of Biotin-X-DSPE
in the formulation and by administering 50 Ag neutravidin.
One concern about the methodology described here is the
extravasation of neutravidin into the tumor compartment
leading to subsequent interaction with the biotinylated lip-
osomes. We acknowledge that this possibility cannot be
ruled out. However, the pool of liposomes in the blood
compartment is much higher relative to that in tumor tissues,
and this increases the likelihood of quicker access and
binding of liposomes to neutravidin, thus minimizing the
amount of neutravidin that can access the tumor site. If
aggregates do form, they may have difficulty in effluxing
out, based on the vascular pore cutoff size (380–780 nm) of
the tumor microvessels [17]. The result would be a smaller
pool of extravasated, ‘‘monomeric’’ liposomes available for
effluxing back out into the blood compartment, and multi-
phasic efflux kinetics would have been predicted, which is
not what we observed. Another concern is the interaction of
neutravidin remaining in circulation with the effluxed lip-
osomes. From a previous study, the plasma elimination of
neutravidin was rapid, where 50% of injected neutravidin
was removed within 30 min [18]; therefore, the likelihood of
neutravidin interacting with the liposomes that have
effluxed back to circulation would be relatively low. Fur-
thermore, the pool of effluxed liposomes is relatively small,
which would also limit their interactions with the remaining
neutravidin (already low in plasma levels).
Using the LS180 solid tumor model, we characterized the
tumor efflux of liposomes at 4 h after tumor accumulation.
The efflux profile, by itself, can be used graphically for
comparisons, for example, by overlapping two different
efflux curves of interest and qualitatively making compar-
isons between them. A more quantitative measure is the
tumor influx (k1) and efflux (k 1) rate constants that were
also determined in this study. The influx and efflux rate
constants were calculated to be 0.022 and 0.041 h 1, respec-
tively, at 4 h after accumulation in LS180 tumors. These rate
constants can provide insights to the influx and efflux
processes, and can serve as comparators for other tumor
models and/or liposome formulations. It is important to note
that the rate constants are estimates, given the variability
involved in the animal studies, and that the data pertain to the
0–4 h time frame. Thus, this approach may be useful in
determining liposome influx and efflux kinetics properties at
different times post injection. In the present study, the efflux
rate constant was elevated by approximately 2-fold over the
influx rate constant. This is consistent with the high hydro-
static pressure that exists in solid tumors [19,20].
The results presented here demonstrate the utility of the
plasma liposome quenching method in characterizing the
detailed tumor accumulation kinetics of liposomes. This
model can potentially serve as a very useful, versatile tool
for characterizing and comparing tumor accumulation
kinetics of numerous combinations of liposome parameters
and tumor models. The pharmacokinetics of different lipid
formulations, different doses and even different liposome
sizes in various tumor models can be studied. This applica-
tion allows a better understanding of the mechanisms under-
lying accumulation of liposomes in tumor, and may be
useful in optimizing therapeutic liposome formulations
designed to treat solid tumors.
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